Thumbnail
Access Restriction
Open

Author Ming, Wei ♦ Lu, Gan ♦ Xin, Sha ♦ Huanyu, Lu ♦ Yinghao, Jiang ♦ Xiaoying, Lei ♦ Chengming, Xu ♦ Banjun, Ruan ♦ Li, Wang
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword APPLIED LIFE SCIENCES ♦ ABSORPTION SPECTROSCOPY ♦ COMPUTERIZED TOMOGRAPHY ♦ CONNECTIVE TISSUE CELLS ♦ GENES ♦ IN VIVO ♦ INHIBITION ♦ LIGANDS ♦ MICE ♦ MITOCHONDRIA ♦ OSTEOPOROSIS ♦ OVARIES ♦ PEPTIDES ♦ RECEPTORS ♦ SKELETON
Abstract Therapeutic targeting bone loss has been the focus of the study in osteoporosis. The present study is intended to evaluate whether MOTS-c, a novel mitochondria related 16 aa peptide, can protect mice from ovariectomy-induced osteoporosis. After ovary removal, the mice were injected with MOTS-c at a dose of 5 mg/kg once a day for 12 weeks. Our results showed that MOTS-c treatment significantly alleviated bone loss, as determined by micro-CT examination. Mechanistically, we found that the receptor activator of nuclear factor-κB ligand (RANKL) induced osteoclast differentiation was remarkably inhibited by MOTS-c. Moreover, MOTS-c increased phosphorylated AMPK levels, and compound C, an AMPK inhibitor, could partially abrogate the effects of the MOTS-c on osteoclastogenesis. Thus, our findings provide evidence that MOTS-c may exert as an inhibitor of osteoporosis via AMPK dependent inhibition of osteoclastogenesis. -- Highlights: •MOTS-c decreases OVX-induced bone loss in vivo. •MOTS-c inhibits RANKL-induced osteoclast formation. •MOTS-c inhibits RANKL-induced osteoclast-specific gene expression. •MOTS-c represses osteoclast differentiation via the activation of AMPK.
ISSN 0006291X
Educational Use Research
Learning Resource Type Article
Publisher Date 2016-08-05
Publisher Place United States
Journal Biochemical and Biophysical Research Communications
Volume Number 476
Issue Number 4


Open content in new tab

   Open content in new tab